Newer systemic treatments for advanced hepatocellular carcinoma (HCC) include immune checkpoint blockade (ICB) which act through increasing cytotoxic T-cell mediated response to tumor. There is a lack of biomarkers of ICB response and treatment outcomes are not correlated with change in tumor size. We evaluated MRI imaging features of HCC and change in tumor stiffness after 6 weeks immunotherapy in surgical and non-surgical patients. An increase in HCC stiffness on MRE after 6 weeks treatment was significantly correlated with treatment response. Longitudinal measurement of tumor stiffness on MRE provides a novel technique for early immunotherapy response assessment.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords